Ignite Creation Date:
2025-12-24 @ 11:14 PM
Ignite Modification Date:
2026-01-02 @ 12:09 AM
Study NCT ID:
NCT05828069
Status:
RECRUITING
Last Update Posted:
2025-12-19
First Post:
2023-04-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006646', 'term': 'Histiocytosis, Langerhans-Cell'}], 'ancestors': [{'id': 'D017563', 'term': 'Lung Diseases, Interstitial'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D015614', 'term': 'Histiocytosis'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D013048', 'term': 'Specimen Handling'}, {'id': 'D001706', 'term': 'Biopsy'}, {'id': 'D013129', 'term': 'Spinal Puncture'}, {'id': 'C000626518', 'term': 'tovorafenib'}], 'ancestors': [{'id': 'D019411', 'term': 'Clinical Laboratory Techniques'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D003581', 'term': 'Cytodiagnosis'}, {'id': 'D003584', 'term': 'Cytological Techniques'}, {'id': 'D003949', 'term': 'Diagnostic Techniques, Surgical'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}, {'id': 'D003943', 'term': 'Diagnostic Techniques, Neurological'}, {'id': 'D011677', 'term': 'Punctures'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 48}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-03-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-07', 'completionDateStruct': {'date': '2028-09-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-18', 'studyFirstSubmitDate': '2023-04-21', 'studyFirstSubmitQcDate': '2023-04-21', 'lastUpdatePostDateStruct': {'date': '2025-12-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2023-04-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-09-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Percent peripheral blood mononuclear cells with mutated allele', 'timeFrame': 'Up to 2 years', 'description': 'Will be analyzed descriptively using logistic regression with complete response/progressive response vs. stable disease/progressive disease as the response variable.'}], 'primaryOutcomes': [{'measure': 'Frequency of dose limiting toxicity (dose finding phase)', 'timeFrame': 'Up to 28 days', 'description': 'Will be analyzed descriptively.'}, {'measure': 'Overall response rate (phase II)', 'timeFrame': 'After 2 cycles of therapy (each cycle is 28 days)', 'description': "Will be assessed using minimax Simon's two-stage designs in each of the BRAFV600E and non-BRAFV600E cohorts separately. The two arms will not be directly compared. The 95% confidence interval for the overall response rate will be adjusted for the two-stage design."}], 'secondaryOutcomes': [{'measure': 'Event free survival rate', 'timeFrame': 'At 1 and 2 years', 'description': 'Will be estimated by the Kaplan-Meier method beginning at study enrollment. Will be evaluated two years after enrollment of the last patient on the trial and estimates at specific timepoints will be presented along with log-log transformed 95% confidence intervals. Events are defined as relapse/progression, second malignant neoplasm, or death.'}, {'measure': 'Progression free survival rate', 'timeFrame': 'Up to 2 years', 'description': 'Will be estimated by the Kaplan-Meier method beginning at study enrollment. Will be evaluated by two years after enrollment of the last patient on the trial and estimates at specific timepoints will be presented along with log-log transformed 95% confidence intervals.'}, {'measure': 'Duration of response rate', 'timeFrame': 'After 12 months of therapy. From the scan confirming the complete response or partial response (whichever is recorded first), until the first occurrence of recurrent or progressive disease or death (event) or last known status on trial', 'description': 'Response is based on modified Response Evaluation Critieria for Solid Tumors (RECIST)/Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) consistent with other recent pediatric Langerhans Cell Histiocytosis trials (NCT02670707 and NCT04079179) and adult histiocytosis trials with MAPK inhibitors. Comparison of response assessed via RECIST vs PERCIST will be analyzed by displaying two-way tables of the responses with no formal statistical testing.'}, {'measure': 'Overall survival rate', 'timeFrame': 'Up to 2 years', 'description': 'Will be estimated by the Kaplan-Meier method beginning at study enrollment. Will be evaluated two years after enrollment of the last patient on the trial and estimates at specific timepoints will be presented along with log-log transformed 95% confidence intervals.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Recurrent Langerhans Cell Histiocytosis', 'Refractory Langerhans Cell Histiocytosis']}, 'descriptionModule': {'briefSummary': 'This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form tumors in certain tissues and organs including bones, skin, lungs and pituitary gland and can damage them. This tumor is more common in children and young adults. DAY101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Using DAY101 may be effective in treating patients with relapsed or refractory Langerhans cell histiocytosis.', 'detailedDescription': 'PRIMARY OBJECTIVE:\n\nI. To determine overall response rate (ORR) for children and young adults with relapsed or refractory BRAFV600E positive (cohort 1) and BRAFV600E negative (cohort 2) Langerhans cell histiocytosis (LCH) treated with tovorafenib (DAY101) after 2 cycles and must be maintained 4 weeks later.\n\nSECONDARY OBJECTIVES:\n\nI. To determine nature and severity of adverse events in patients treated with tovorafenib (DAY101) for relapsed or refractory LCH.\n\nII. To describe event-free survival (EFS) at 1 year in children and young adults with relapsed and refractory LCH treated with tovorafenib (DAY 101) for up to 1 year.\n\nIII. To determine durability of response in children and young adults with relapsed or refractory LCH treated with tovorafenib (DAY101) following cessation of therapy in patients with complete response (CR) at 1 year.\n\nIV. To describe progression-free (and relapse-free) survival (PFS) and overall survival (OS) in children and young adults with relapsed or refractory LCH treated with tovorafenib (DAY101) for up to 1 year.\n\nEXPLORATORY OBJECTIVES:\n\nI. To determine potential role of pathogenic tumor mutation in response to tovorafenib (DAY101), and to evaluate changes in bone marrow and peripheral blood cell populations carrying pathogenic mutations in response to tovorafenib (DAY101) therapy.\n\nIa. To define somatic mutations in LCH lesion biopsies; Ib. To determine impact of tovorafenib (DAY101) on bone marrow and blood BRAFV600E+ mononuclear cells; Ic. To determine impact of tovorafenib (DAY101) on cerebral spinal fluid and disease response; Id. To determine the performance of standardized immunohistochemical analysis of LCH lesion biopsies.\n\nII. To compare performance of LCH-specific response criteria to Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\n\nIII. To describe the pharmacokinetics of tovorafenib (DAY101) when administered to pediatric and young adult patients with relapse or refractory LCH.\n\nOUTLINE: This is a dose escalation study of tovorafenib followed by a phase II trial.\n\nPatients receive tovorafenib orally (PO) once weekly (QW) on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-gated acquisition (MUGA) or echocardiography (ECHO) scans, and fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) or computed tomography (CT) throughout the trial, and collection of blood and urine samples on study. Patients with suspicion of bone marrow and/or central nervous system involvement will also undergo bone marrow biopsy and aspiration and lumbar puncture on study and during follow up.\n\nAfter completion of study treatment, patients are followed up at 28 days, months 3, 6, 9, and 12, and then at 2 years post cycle 12.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '22 Years', 'minimumAge': '180 Days', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* 180 days- \\< 22 years (at time of study enrollment)\n* Patient must have a body surface area of ≥ 0.3 m\\^2\n* Patients with progressive, relapsed, or recurrent LCH with measurable disease at study entry\n\n * Patients must have had histologic verification of LCH (from either original diagnosis or relapse/progression) at the time of study entry (must be obtained within 28 days prior to enrollment and start of protocol therapy) (repeat if necessary)\n\n * Tissue confirmation of relapse is recommended but not required\n * Pathology report must be submitted for central confirmation of diagnosis within 7 days of enrollment.\n * Formalin-fixed paraffin-embedded (FFPE) blocks or unstained slides (initial diagnosis and/or subsequent biopsies) will be required for retrospective central confirmation of diagnosis and molecular studies\n * Patients with mixed histiocytic disorders (e.g. LCH with juvenile xanthogranuloma) may be included\n * Patients must have measurable disease, documented by radiographic imaging (LCH- specific response criteria (must be obtained within 28 days prior to enrollment and start of protocol therapy) (repeat if necessary).\n * Patients must have progressive or refractory disease or experience relapse after at least one previous systemic treatment strategy\n * Pathogenic somatic mutation detected in genes encoding tyrosine kinase receptors (CSFR1, ERBB3 or ALK), RAS or RAF (may be from original or subsequent biopsy or peripheral blood/bone marrow aspirate). Clinical mutation reports may include quantitative polymerase chain reaction (PCR) (e.g. BRAFV600E) and/or Sanger or next generation sequencing. Immunohistochemistry (e.g. VE1 antibody for BRAFV600E) alone is not sufficient\n* Participant must be able to take an enteral dose and formulation of medication. Study medication is only available as an oral suspension or tablet, which may be taken by mouth or other enteral route such as nasogastric, jejunostomy, or gastric tube\n* Karnofsky \\>= 50% for patients \\> 16 years of age and Lansky \\>= 50% for patients =\\< 16 years of age\n* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \\> 16 years of age and Lansky for patients =\\< 16 years of age\n* Myelosuppressive chemotherapy: Patients must not have received within 14 days of entry onto this study\n* Investigational agent or any other anticancer therapy not defined above: Patients must not have received any investigational agent or any other anticancer therapy (including MAPK pathway inhibitor) for at least 14 days prior to planned start of tovorafenib (DAY101)\n* Radiation therapy (RT): Patient must not have received RT within 2 weeks after the last dose fraction of RT\n* Patients must have fully recovered from any prior surgery\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, targeted inhibitor, and/or radiotherapy with toxicities reduced to grade 1 or less (Common Terminology Criteria for Adverse Events \\[CTCAE\\] version 5.0)\n* Steroids: =\\< 0.5 mg/kg/day of prednisone equivalent (maximum 20 mg/day) averaged during the month prior to study enrollment is permissible\n* Strong inducers or inhibitors of CYP2C8 are prohibited for 14 days before the first dose of tovorafenib (DAY101) and from planned administration for the duration of study participation\n* Medications that are breast cancer resistant protein (BCRP) substrates that have a narrow therapeutic index are prohibited for 14 days before the first dose of tovorafenib (DAY101) and for the duration of study participation\n* Peripheral absolute neutrophil count (ANC) \\>= 750/uL unless secondary to bone marrow involvement, in such cases bone marrow involvement must be documented (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \\> 7 days have elapsed from their most recent prior assessment)\n* Platelet count \\>= 75,000/uL (unsupported/without transfusion within the past 7 days) (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \\> 7 days have elapsed from their most recent prior assessment)\n* Patients with marrow disease must have platelet count of \\>= 75,000/uL (transfusion support allowed) and must not be refractory to platelet transfusions. Bone marrow involvement must be documented\n* Hemoglobin \\>= 8 g/dL (unsupported/without transfusion within the past 7 days). Patients with marrow disease must have hemoglobin \\>= 8 g/dL (transfusion support allowed). Bone marrow involvement must be documented\n* Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g., Neulasta \\[registered trademark\\]) or 7 days for short-acting growth factor\n* A serum creatinine based on age/sex as follows (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \\> 7 days have elapsed from their most recent prior assessment)\n\n * Age: 6 months to \\< 1 year; Maximum Serum Creatinine (mg/dL):= 0.5 mg/dl (male and female)\n * Age: 1 to \\< 2 years; Maximum Serum Creatinine (mg/dL): = 0.6 mg/dl (male and female)\n * Age: 2 to \\< 6 years; Maximum Serum Creatinine (mg/dL): = 0.8 mg/dl (male and female)\n * Age: 6 to \\< 10 years; Maximum Serum Creatinine (mg/dL): = 1.0 mg/dl (male and female)\n * Age: 10 to \\< 13 years; Maximum Serum Creatinine (mg/dL): = 1.2 mg/dl (male and female)\n * 13 to \\< 16 years; Maximum Serum Creatinine (mg/dL): = 1.5 mg/dl (male) and 1.4 mg/dl (female)\n * Age: \\>= 16 years; Maximum Serum Creatinine (mg/dL): = 1.7 mg/dl (male) and 1.4 mg/dl (female)\n * OR- a 24 hour urine creatinine clearance \\>= 50 mL/min/1.73 m\\^2\n * OR- a glomerular filtration rate (GFR) \\>= 50 mL/min/1.73 m\\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)\n * Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility\n* Bilirubin (sum of conjugated + unconjugated) =\\< 1.5 x upper limit of normal (ULN) for age (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \\> 7 days have elapsed from their most recent prior assessment)\n* Alanine aminotransferase (ALT) =\\< 3 x ULN for age (must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \\> 7 days have elapsed from their most recent prior assessment)\n* Serum albumin \\>= 2 g/dl must be performed within 7 days prior to enrollment, must be repeated prior to the start of protocol therapy if \\> 7 days have elapsed from their most recent prior assessment)\n* For patients with liver disease caused by their histiocytic disorder (as evaluated on radiographic imaging or biopsy): patients may be enrolled with abnormal bilirubin, aspartate aminotransferase (AST), ALT and albumin with documentation of histiocytic liver disease\n* Fractional shortening (FS) of \\>= 25% or ejection fraction of \\>= 50%, as determined by echocardiography or multigated acquisition scan (MUGA) within 28 days prior to study enrollment. Depending on institutional standard, either FS or left ventricular ejection fraction (LVEF) is adequate for enrollment if only one value is measured; if both values are measured, then both values must meet criteria above (must be obtained within 28 days prior to enrollment and start of protocol therapy) (repeat if necessary)\n* No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \\> 94% if there is clinical indication for determination; unless it is due to underlying pulmonary LCH\n* Central Nervous System Function Defined As:\n\n * Patients with seizure disorder may be enrolled if well controlled\n * Central nervous system (CNS) toxicity =\\< Grade 2\n* Human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial unless antiretroviral therapy interacts with the metabolism of tovorafenib (DAY101) and cannot safely be changed to antivirals that do not interact with study medication\n\nExclusion Criteria:\n\n* LCH arising along with other hematologic malignancy (e.g. mixed LCH with acute lymphoblastic leukemia) or any history of non-histiocytic malignancy\n* Disease scenarios as below will be excluded\n\n * Skin-limited disease\n * Gastrointestinal (GI) tract involvement only (those that have disease that can be determined by endoscopic biopsies only)\n * LCH-associated neurodegeneration (LCH-ND) without parenchymal lesions or other systemic lesions\n* Patients with activating mutations in MAP2K1 are not eligible for this study due to drug target specificity. Mutation status will be submitted to study team within 7 days of enrollment\n* Refractory nausea and vomiting, malabsorption, or external biliary shunt that would preclude adequate absorption of tovorafenib (DAY101)\n* Uncontrolled systemic bacterial, viral, or fungal infection\n* Major surgical procedure or significant traumatic injury within 14 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device or minor surgery is permitted within fourteen (14) days of study enrollment (provided that the wound has healed)\n* History of significant bowel resection that would preclude adequate absorption or other significant malabsorptive disease\n* Ophthalmologic considerations: Patients with known significant ophthalmologic conditions or known risk factors for retinal vein occlusion (RVO) or central serous retinopathy (CSR) are not eligible\n* History of solid organ or hematopoietic bone marrow transplantation\n* Clinically significant active cardiovascular disease, or history of myocardial infarction, or deep vein thrombosis/pulmonary embolism within 6 months prior to enrollment, ongoing cardiomyopathy, or current prolonged QT interval \\> 440 ms based on triplicate electrocardiogram (ECG) average\n* History of Grade \\>= 2 CNS hemorrhage or history of any CNS hemorrhage within 28 days of study entry\n* History of any drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome or Stevens Johnsons syndrome (SJS) or who are allergic to tovorafenib (DAY101) or any of its components\n* CTCAE version (V). 5.0 Grade 3 symptomatic creatinine kinase (CPK) elevation ( \\> 5 x ULN)\n* Female patients who are pregnant are ineligible. A pregnancy test is required for female patients of childbearing potential\n* Lactating females who plan to breastfeed their infants are ineligible\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation are ineligible. Women of childbearing potential must use non-hormonal contraception during tovorafenib treatment and for at least 28 days after the last dose. Men should use effective contraception and must not father a child while taking tovorafenib and for 14 days after the last dose'}, 'identificationModule': {'nctId': 'NCT05828069', 'briefTitle': 'A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis', 'nctIdAliases': ['NCT05287295'], 'organization': {'class': 'NIH', 'fullName': 'National Cancer Institute (NCI)'}, 'officialTitle': 'Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis', 'orgStudyIdInfo': {'id': 'NCI-2022-06282'}, 'secondaryIdInfos': [{'id': 'NCI-2022-06282', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': 'ANHL2121', 'type': 'OTHER', 'domain': "Children's Oncology Group"}, {'id': 'ANHL2121', 'type': 'OTHER', 'domain': 'CTEP'}, {'id': 'U10CA180886', 'link': 'https://reporter.nih.gov/quickSearch/U10CA180886', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment (tovorafenib)', 'description': 'Patients receive tovorafenib PO QW on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO scans, and FDG-PET or CT throughout the trial, and collection of blood and urine samples on study. Patients with suspicion of bone marrow and/or central nervous system involvement will also undergo bone marrow biopsy and aspiration and lumbar puncture on study and during follow up.', 'interventionNames': ['Procedure: Biospecimen Collection', 'Procedure: Bone Marrow Aspiration', 'Procedure: Bone Marrow Biopsy', 'Procedure: Computed Tomography', 'Procedure: Echocardiography Test', 'Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan', 'Procedure: Lumbar Puncture', 'Procedure: Multigated Acquisition Scan', 'Drug: Tovorafenib']}], 'interventions': [{'name': 'Biospecimen Collection', 'type': 'PROCEDURE', 'otherNames': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'description': 'Undergo collection of blood and urine samples', 'armGroupLabels': ['Treatment (tovorafenib)']}, {'name': 'Bone Marrow Aspiration', 'type': 'PROCEDURE', 'description': 'Undergo bone marrow aspiration', 'armGroupLabels': ['Treatment (tovorafenib)']}, {'name': 'Bone Marrow Biopsy', 'type': 'PROCEDURE', 'otherNames': ['Biopsy of Bone Marrow', 'Biopsy, Bone Marrow'], 'description': 'Undergo bone marrow biopsy', 'armGroupLabels': ['Treatment (tovorafenib)']}, {'name': 'Computed Tomography', 'type': 'PROCEDURE', 'otherNames': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'Diagnostic CAT Scan', 'Diagnostic CAT Scan Service Type', 'tomography'], 'description': 'Undergo CT', 'armGroupLabels': ['Treatment (tovorafenib)']}, {'name': 'Echocardiography Test', 'type': 'PROCEDURE', 'otherNames': ['EC', 'Echocardiography'], 'description': 'Undergo ECHO', 'armGroupLabels': ['Treatment (tovorafenib)']}, {'name': 'FDG-Positron Emission Tomography and Computed Tomography Scan', 'type': 'PROCEDURE', 'otherNames': ['FDG PET/CT'], 'description': 'Undergo FDG-PET imaging', 'armGroupLabels': ['Treatment (tovorafenib)']}, {'name': 'Lumbar Puncture', 'type': 'PROCEDURE', 'otherNames': ['LP', 'Spinal Tap'], 'description': 'Undergo lumbar puncture', 'armGroupLabels': ['Treatment (tovorafenib)']}, {'name': 'Multigated Acquisition Scan', 'type': 'PROCEDURE', 'otherNames': ['Blood Pool Scan', 'Equilibrium Radionuclide Angiography', 'Gated Blood Pool Imaging', 'Gated Heart Pool Scan', 'MUGA', 'MUGA Scan', 'Multi-Gated Acquisition Scan', 'Radionuclide Ventriculogram Scan', 'Radionuclide Ventriculography', 'RNV Scan', 'RNVG', 'SYMA Scanning', 'Synchronized Multigated Acquisition Scanning'], 'description': 'Undergo MUGA', 'armGroupLabels': ['Treatment (tovorafenib)']}, {'name': 'Tovorafenib', 'type': 'DRUG', 'otherNames': ['BIIB 024', 'BIIB-024', 'BIIB024', 'DAY 101', 'DAY-101', 'DAY101', 'MLN 2480', 'MLN-2480', 'MLN2480', 'Ojemda', 'pan-RAF Kinase Inhibitor DAY101', 'TAK 580', 'TAK-580', 'TAK580'], 'description': 'Given PO', 'armGroupLabels': ['Treatment (tovorafenib)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35233', 'city': 'Birmingham', 'state': 'Alabama', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'oncologyresearch@peds.uab.edu', 'phone': '205-638-9285'}, {'name': 'Matthew A. Kutny', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital of Alabama", 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '72202-3591', 'city': 'Little Rock', 'state': 'Arkansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '501-364-7373'}, {'name': 'David L. Becton', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Arkansas Children's Hospital", 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '90242', 'city': 'Downey', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '626-564-3455'}, {'name': 'Robert M. Cooper', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Kaiser Permanente Downey Medical Center', 'geoPoint': {'lat': 33.94001, 'lon': -118.13257}}, {'zip': '92354', 'city': 'Loma Linda', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '909-558-4050'}, {'name': 'Albert Kheradpour', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Loma Linda University Medical Center', 'geoPoint': {'lat': 34.04835, 'lon': -117.26115}}, {'zip': '90027', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '323-361-4110'}, {'name': 'Rebecca S. Parker', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital Los Angeles", 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '93636', 'city': 'Madera', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Research@valleychildrens.org', 'phone': '559-353-3000'}, {'name': 'Ruetima Titapiwatanakun', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Valley Children's Hospital", 'geoPoint': {'lat': 36.96134, 'lon': -120.06072}}, {'zip': '94609', 'city': 'Oakland', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'PedOncRschOAK@ucsf.edu', 'phone': '510-428-3264'}, {'name': 'Jennifer G. Michlitsch', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "UCSF Benioff Children's Hospital Oakland", 'geoPoint': {'lat': 37.80437, 'lon': -122.2708}}, {'zip': '94611', 'city': 'Oakland', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kpoct@kp.org', 'phone': '877-642-4691'}, {'name': 'Aarati V. Rao', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Kaiser Permanente-Oakland', 'geoPoint': {'lat': 37.80437, 'lon': -122.2708}}, {'zip': '92868', 'city': 'Orange', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'oncresearch@choc.org', 'phone': '714-509-8646'}, {'name': 'Elyssa M. Rubin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital of Orange County", 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '94304', 'city': 'Palo Alto', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ccto-office@stanford.edu', 'phone': '800-694-0012'}, {'name': 'Jay Michael S. Balagtas', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Lucile Packard Children's Hospital Stanford University", 'geoPoint': {'lat': 37.44188, 'lon': -122.14302}}, {'zip': '94158', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancertrials@ucsf.edu', 'phone': '877-827-3222'}, {'name': 'Natalie L. Wu', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UCSF Medical Center-Mission Bay', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'josh.b.gordon@nsmtp.kp.org', 'phone': '303-764-5056'}, {'name': 'Timothy P. Garrington', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital Colorado", 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '80218', 'city': 'Denver', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'PSGResearchSharedMailbox@HCAHealthcare.com', 'phone': '303-832-2344'}, {'name': 'Florence Choo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center", 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '06106', 'city': 'Hartford', 'state': 'Connecticut', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '860-545-9981'}, {'name': 'Michael S. Isakoff', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Connecticut Children's Medical Center", 'geoPoint': {'lat': 41.76371, 'lon': -72.68509}}, {'zip': '06520', 'city': 'New Haven', 'state': 'Connecticut', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'canceranswers@yale.edu', 'phone': '203-785-5702'}, {'name': 'Farzana Pashankar', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Yale University', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '19803', 'city': 'Wilmington', 'state': 'Delaware', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Allison.bruce@nemours.org', 'phone': '302-651-5572'}, {'name': 'Vibhuti Agarwal', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Alfred I duPont Hospital for Children', 'geoPoint': {'lat': 39.74595, 'lon': -75.54659}}, {'zip': '20010', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'OncCRC_OnCall@childrensnational.org', 'phone': '202-476-2800'}, {'name': 'Jeffrey S. Dome', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's National Medical Center", 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '33908', 'city': 'Fort Myers', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'molly.arnstrom@leehealth.org', 'phone': '239-343-5333'}, {'name': 'Emad K. Salman', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Golisano Children's Hospital of Southwest Florida", 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}, {'zip': '32610', 'city': 'Gainesville', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancer-center@ufl.edu', 'phone': '352-273-8010'}, {'name': 'Brian Stover', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UF Health Cancer Institute - Gainesville', 'geoPoint': {'lat': 29.65163, 'lon': -82.32483}}, {'zip': '32207', 'city': 'Jacksonville', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Allison.bruce@nemours.org', 'phone': '302-651-5572'}, {'name': 'Vibhuti Agarwal', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Nemours Children's Clinic-Jacksonville", 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33136', 'city': 'Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '305-243-2647'}, {'name': 'Warren Alperstein', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Miami Miller School of Medicine-Sylvester Cancer Center', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33155', 'city': 'Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '888-624-2778'}, {'name': 'Maggie E. Fader', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Nicklaus Children's Hospital", 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '32806', 'city': 'Orlando', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Jennifer.spinelli@orlandohealth.com', 'phone': '321-841-5357'}, {'name': 'Jaime M. Libes-Bander', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Arnold Palmer Hospital for Children', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32827', 'city': 'Orlando', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Allison.bruce@nemours.org', 'phone': '302-651-5572'}, {'name': 'Vibhuti Agarwal', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Nemours Children's Hospital", 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32504', 'city': 'Pensacola', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'helpdesk@childrensoncologygroup.org'}, {'name': 'Jeffrey H. Schwartz', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Nemours Children's Clinic - Pensacola", 'geoPoint': {'lat': 30.42131, 'lon': -87.21691}}, {'zip': '33607', 'city': 'Tampa', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'jennifer.manns@baycare.org', 'phone': '813-357-0849'}, {'name': 'Don E. Eslin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Saint Joseph's Hospital/Children's Hospital-Tampa", 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30329', 'city': 'Atlanta', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Olivia.Floyd@choa.org', 'phone': '404-785-0232'}, {'name': 'Kathryn S. Sutton', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Healthcare of Atlanta - Arthur M Blank Hospital", 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '31404', 'city': 'Savannah', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Lorraine.OHara@hcahealthcare.com', 'phone': '912-350-7887'}, {'name': 'Andrew L. Pendleton', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Memorial Health University Medical Center', 'geoPoint': {'lat': 32.08354, 'lon': -81.09983}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '773-880-4562'}, {'name': 'Joanna L. Weinstein', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Lurie Children's Hospital-Chicago", 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60637', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancerclinicaltrials@bsd.uchicago.edu', 'phone': '773-702-8222'}, {'name': 'Perry C. Morocco', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Chicago Comprehensive Cancer Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '61637', 'city': 'Peoria', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '888-226-4343'}, {'name': 'Prerna Kumar', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Saint Jude Midwest Affiliate', 'geoPoint': {'lat': 40.69365, 'lon': -89.58899}}, {'zip': '46202', 'city': 'Indianapolis', 'state': 'Indiana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '800-248-1199'}, {'name': 'Anthony Ross', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Riley Hospital for Children', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '50309', 'city': 'Des Moines', 'state': 'Iowa', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'samantha.mallory@unitypoint.org', 'phone': '515-241-8912'}, {'name': 'Samantha L. Mallory', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Blank Children's Hospital", 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '800-237-1225'}, {'name': 'David S. Dickens', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Iowa/Holden Comprehensive Cancer Center', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '40536', 'city': 'Lexington', 'state': 'Kentucky', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '859-257-3379'}, {'name': 'James T. Badgett', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Kentucky/Markey Cancer Center', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'zip': '70118', 'city': 'New Orleans', 'state': 'Louisiana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '504-894-5377'}, {'name': 'Maria C. Velez-Yanguas', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital New Orleans", 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '70121', 'city': 'New Orleans', 'state': 'Louisiana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Elisemarie.curry@ochsner.org', 'phone': '504-842-8084'}, {'name': 'Craig Lotterman', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Ochsner Medical Center Jefferson', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '21215', 'city': 'Baltimore', 'state': 'Maryland', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '410-601-9083'}, {'name': 'Jason M. Fixler', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Sinai Hospital of Baltimore', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '48823', 'city': 'East Lansing', 'state': 'Michigan', 'status': 'SUSPENDED', 'country': 'United States', 'facility': 'Michigan State University', 'geoPoint': {'lat': 42.73698, 'lon': -84.48387}}, {'zip': '49503', 'city': 'Grand Rapids', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'crcwm-regulatory@crcwm.org', 'phone': '616-391-1230'}, {'name': 'Kathleen Y. Butler', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital", 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'zip': '49007', 'city': 'Kalamazoo', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'crcwm-regulatory@crcwm.org', 'phone': '616-391-1230'}, {'name': 'Kathleen Y. Butler', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Bronson Methodist Hospital', 'geoPoint': {'lat': 42.29171, 'lon': -85.58723}}, {'zip': '55404', 'city': 'Minneapolis', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'pauline.mitby@childrensmn.org', 'phone': '612-813-5913'}, {'name': 'Michael K. Richards', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospitals and Clinics of Minnesota - Minneapolis", 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '55455', 'city': 'Minneapolis', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '612-624-2620'}, {'name': 'Lucie M. Turcotte', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Minnesota/Masonic Cancer Center', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '39216', 'city': 'Jackson', 'state': 'Mississippi', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '601-815-6700'}, {'name': 'Betty L. Herrington', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Mississippi Medical Center', 'geoPoint': {'lat': 32.29876, 'lon': -90.18481}}, {'zip': '63104', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '314-268-4000'}, {'name': 'William S. Ferguson', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Cardinal Glennon Children's Medical Center", 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'info@siteman.wustl.edu', 'phone': '800-600-3606'}, {'name': 'Bryan A. Sisk', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Washington University School of Medicine', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '63141', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '314-251-7066'}, {'name': 'Robin D. Hanson', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mercy Hospital Saint Louis', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '68114', 'city': 'Omaha', 'state': 'Nebraska', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '402-955-3949'}, {'name': 'Jill C. Beck', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital and Medical Center of Omaha", 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68198', 'city': 'Omaha', 'state': 'Nebraska', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'unmcrsa@unmc.edu', 'phone': '402-559-6941'}, {'name': 'Jill C. Beck', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Nebraska Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '89135', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'research@sncrf.org', 'phone': '702-384-0013'}, {'name': 'Alan K. Ikeda', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Alliance for Childhood Diseases/Cure 4 the Kids Foundation', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '89144', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'research@sncrf.org', 'phone': '702-384-0013'}, {'name': 'Alan K. Ikeda', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Summerlin Hospital Medical Center', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '07601', 'city': 'Hackensack', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '551-996-2897'}, {'name': 'Katharine Offer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hackensack University Medical Center', 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}}, {'zip': '08903', 'city': 'New Brunswick', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '732-235-8675'}, {'name': 'Marissa Botwinick', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital', 'geoPoint': {'lat': 40.48622, 'lon': -74.45182}}, {'zip': '07503', 'city': 'Paterson', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'HallL@sjhmc.org', 'phone': '973-754-2207'}, {'name': 'Alissa Kahn', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Saint Joseph's Regional Medical Center", 'geoPoint': {'lat': 40.91677, 'lon': -74.17181}}, {'zip': '12208', 'city': 'Albany', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '518-262-5513'}, {'name': 'Lauren R. Weintraub', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Albany Medical Center', 'geoPoint': {'lat': 42.65258, 'lon': -73.75623}}, {'zip': '11219', 'city': 'Brooklyn', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '718-765-2500'}, {'name': 'Mahmut Y. Celiker', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Maimonides Medical Center', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}}, {'zip': '11040', 'city': 'New Hyde Park', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '718-470-3460'}, {'name': 'Julie I. Krystal', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "The Steven and Alexandra Cohen Children's Medical Center of New York", 'geoPoint': {'lat': 40.7351, 'lon': -73.68791}}, {'zip': '10016', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CancerTrials@nyulangone.org'}, {'name': 'Elizabeth A. Raetz', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Laura and Isaac Perlmutter Cancer Center at NYU Langone', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10032', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancerclinicaltrials@cumc.columbia.edu', 'phone': '212-342-5162'}, {'name': 'Nobuko Hijiya', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '212-639-7592'}, {'name': 'Christopher J. Forlenza', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Memorial Sloan Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '212-746-1848'}, {'name': 'Nitya Gulati', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'NYP/Weill Cornell Medical Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '13210', 'city': 'Syracuse', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '315-464-5476'}, {'name': 'Melanie A. Comito', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'State University of New York Upstate Medical University', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}}, {'zip': '10467', 'city': 'The Bronx', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'eskwak@montefiore.org', 'phone': '718-379-6866'}, {'name': 'Alice Lee', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Montefiore Medical Center - Moses Campus', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '10595', 'city': 'Valhalla', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '914-594-3794'}, {'name': 'Jessica C. Hochberg', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'New York Medical College', 'geoPoint': {'lat': 41.07482, 'lon': -73.77513}}, {'zip': '28801', 'city': 'Asheville', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'NCDV.ResearchRegulatory@HCAHealthcare.com', 'phone': '828-213-7055'}, {'name': 'Douglas J. Scothorn', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mission Hospital', 'geoPoint': {'lat': 35.60095, 'lon': -82.55402}}, {'zip': '27710', 'city': 'Durham', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '888-275-3853'}, {'name': 'Jessica M. Sun', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Duke University Medical Center', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '27834', 'city': 'Greenville', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'eubankss@ecu.edu', 'phone': '252-744-1015'}, {'name': 'Andrea R. Whitfield', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'East Carolina University', 'geoPoint': {'lat': 35.61266, 'lon': -77.36635}}, {'zip': '27157', 'city': 'Winston-Salem', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '336-713-6771'}, {'name': 'Thomas W. McLean', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Wake Forest University Health Sciences', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '216-844-5437'}, {'name': 'Duncan S. Stearns', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Rainbow Babies and Childrens Hospital', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '43205', 'city': 'Columbus', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Melinda.Triplet@nationwidechildrens.org', 'phone': '614-722-6039'}, {'name': 'Mark A. Ranalli', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Nationwide Children's Hospital", 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '45404', 'city': 'Dayton', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '800-228-4055'}, {'name': 'Jordan M. Wright', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Dayton Children's Hospital", 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '73104', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ou-clinical-trials@ouhsc.edu', 'phone': '405-271-8777'}, {'name': 'Rene Y. McNall-Knapp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Oklahoma Health Sciences Center', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'trials@ohsu.edu', 'phone': '503-494-1080'}, {'name': 'Katrina Winsnes', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Oregon Health and Science University', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '17822', 'city': 'Danville', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'HemonCCTrials@geisinger.edu', 'phone': '570-271-5251'}, {'name': 'Jagadeesh Ramdas', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Geisinger Medical Center', 'geoPoint': {'lat': 40.96342, 'lon': -76.61273}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CancerTrials@email.chop.edu', 'phone': '267-425-5544'}, {'name': 'Michael D. Hogarty', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital of Philadelphia", 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '19134', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '215-427-8991'}, {'name': 'Gregory E. Halligan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Saint Christopher's Hospital for Children", 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '15224', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'jean.tersak@chp.edu', 'phone': '412-692-8570'}, {'name': 'Julia E. Segal', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital of Pittsburgh of UPMC", 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '29203', 'city': 'Columbia', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kim.Williams3@prismahealth.org', 'phone': '864-522-4317'}, {'name': 'Stuart L. Cramer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Prisma Health Richland Hospital', 'geoPoint': {'lat': 34.00071, 'lon': -81.03481}}, {'zip': '29605', 'city': 'Greenville', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kim.Williams3@prismahealth.org', 'phone': '864-522-4317'}, {'name': 'Aniket Saha', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "BI-LO Charities Children's Cancer Center", 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '37916', 'city': 'Knoxville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '865-541-8266'}, {'name': 'Susan E. Spiller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'East Tennessee Childrens Hospital', 'geoPoint': {'lat': 35.96064, 'lon': -83.92074}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '615-342-1919'}, {'name': 'Clinton M. Carroll', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "The Children's Hospital at TriStar Centennial", 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '37232', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '800-811-8480'}, {'name': 'Devang J. Pastakia', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Vanderbilt University/Ingram Cancer Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '78723', 'city': 'Austin', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'TXAUS-DL-SFCHemonc.research@ascension.org', 'phone': '512-628-1902'}, {'name': 'Shannon M. Cohn', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Dell Children's Medical Center of Central Texas", 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'canceranswerline@UTSouthwestern.edu', 'phone': '214-648-7097'}, {'name': 'Erin B. Butler', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UT Southwestern/Simmons Cancer Center-Dallas', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '79905', 'city': 'El Paso', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ranjan.bista@ttuhsc.edu', 'phone': '915-298-5444'}, {'name': 'Benjamin Carcamo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "El Paso Children's Hospital", 'geoPoint': {'lat': 31.75872, 'lon': -106.48693}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'burton@bcm.edu', 'phone': '713-798-1354'}, {'name': 'Olive S. Eckstein', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'askmdanderson@mdanderson.org', 'phone': '877-632-6789'}, {'name': 'Najat C. Daw', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'M D Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78207', 'city': 'San Antonio', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'bridget.medina@christushealth.org', 'phone': '210-704-2894'}, {'name': 'Julie Voeller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital of San Antonio", 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Vinod.GidvaniDiaz@hcahealthcare.com', 'phone': '210-575-6240'}, {'name': 'Jose M. Esquilin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Methodist Children's Hospital of South Texas", 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'phoresearchoffice@uthscsa.edu', 'phone': '210-450-3800'}, {'name': 'Allison C. Grimes', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Texas Health Science Center at San Antonio', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '76508', 'city': 'Temple', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '254-724-5407'}, {'name': 'Nicholas W. McGregor', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Scott and White Memorial Hospital', 'geoPoint': {'lat': 31.09823, 'lon': -97.34278}}, {'zip': '84113', 'city': 'Salt Lake City', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '801-585-5270'}, {'name': 'Taumoha Ghosh', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Primary Children's Hospital", 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '22908', 'city': 'Charlottesville', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'uvacancertrials@hscmail.mcc.virginia.edu', 'phone': '434-243-6303'}, {'name': 'Brian C. Belyea', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Virginia Cancer Center', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}, {'zip': '23507', 'city': 'Norfolk', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CCBDCresearch@chkd.org', 'phone': '757-668-7243'}, {'name': 'Melissa S. Mark', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital of The King's Daughters", 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': '23298', 'city': 'Richmond', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CTOclinops@vcu.edu', 'phone': '804-628-6430'}, {'name': 'Nadirah El-Amin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'VCU Massey Comprehensive Cancer Center', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '98105', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '866-987-2000'}, {'name': 'Sarah E. Leary', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Seattle Children's Hospital", 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '99204', 'city': 'Spokane', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'HopeBeginsHere@providence.org', 'phone': '800-228-6618'}, {'name': 'Judy L. Felgenhauer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Providence Sacred Heart Medical Center and Children's Hospital", 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'zip': '25304', 'city': 'Charleston', 'state': 'West Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '304-388-9944'}, {'name': 'Mohamad H. Badawi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'West Virginia University Charleston Division', 'geoPoint': {'lat': 38.34982, 'lon': -81.63262}}, {'zip': '53226', 'city': 'Milwaukee', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'MACCCTO@mcw.edu', 'phone': '414-955-4727'}, {'name': 'Peter H. Shaw', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital of Wisconsin", 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}, {'zip': '2031', 'city': 'Randwick', 'state': 'New South Wales', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '(02) 9382-1721'}, {'name': 'Draga Barbaric', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Sydney Children's Hospital", 'geoPoint': {'lat': -33.91439, 'lon': 151.24895}}, {'zip': '4101', 'city': 'South Brisbane', 'state': 'Queensland', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '61 7 3068 1111'}, {'name': 'Steven A. Foresto', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Queensland Children's Hospital", 'geoPoint': {'lat': -27.48034, 'lon': 153.02049}}, {'zip': '3052', 'city': 'Parkville', 'state': 'Victoria', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Jordan.Hansford@rch.org.au', 'phone': '61 3 9345 5656'}, {'name': 'Martin A. Campbell', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Royal Children's Hospital", 'geoPoint': {'lat': -37.78333, 'lon': 144.95}}, {'zip': '6009', 'city': 'Perth', 'state': 'Western Australia', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'helpdesk@childrensoncologygroup.org'}, {'name': 'Marianne B. Phillips', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Perth Children's Hospital", 'geoPoint': {'lat': -31.95224, 'lon': 115.8614}}, {'zip': 'T6G 2B7', 'city': 'Edmonton', 'state': 'Alberta', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'pedsoncologyresearch@ahs.ca', 'phone': '780-407-8798'}, {'name': 'Sarah J. McKillop', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Alberta Hospital', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'B3K 6R8', 'city': 'Halifax', 'state': 'Nova Scotia', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Research@iwk.nshealth.ca', 'phone': '902-470-8520'}, {'name': 'Craig Erker', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'IWK Health Centre', 'geoPoint': {'lat': 44.64269, 'lon': -63.57688}}, {'zip': 'L8N 3Z5', 'city': 'Hamilton', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '905-521-2100'}, {'name': 'Uma H. Athale', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "McMaster Children's Hospital at Hamilton Health Sciences", 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'N6A 5W9', 'city': 'London', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '519-685-8306'}, {'name': 'Shayna M. Zelcer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital", 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'M5G 1X8', 'city': 'Toronto', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ask.CRS@sickkids.ca', 'phone': '416-813-7654'}, {'name': 'Oussama A. Abla', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital for Sick Children', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'H3T 1C5', 'city': 'Montreal', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'yvan.samson@umontreal.ca', 'phone': '514-345-4931'}, {'name': 'Monia Marzouki', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre Hospitalier Universitaire Sainte-Justine', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'J1H 5N4', 'city': 'Sherbrooke', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'crcinformation.chus@ssss.gouv.qc.ca', 'phone': '819-820-6480'}, {'name': 'Josee Brossard', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre Hospitalier Universitaire de Sherbrooke-Fleurimont', 'geoPoint': {'lat': 45.40008, 'lon': -71.89908}}, {'zip': 'G1V 4G2', 'city': 'Québec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'rechclinique@crchudequebec.ulaval.ca', 'phone': '418-525-4444'}, {'name': 'Bruno Michon', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)", 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}], 'overallOfficials': [{'name': 'Michelle L Hermiston', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Children's Oncology Group"}]}, 'ipdSharingStatementModule': {'url': 'https://grants.nih.gov/policy/sharing.htm', 'ipdSharing': 'YES', 'description': 'NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}, 'responsibleParty': {'type': 'SPONSOR'}}}}